
FDA hits Unicycive with manufacturing-related complete response letter, delaying hopes for kidney disease prospect
Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to patients with chronic kidney disease (CKD) who are on dialysis. The FDA issued the company a complete response letter (CRL), citing …